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Abstract
Background: Overactive bladder is a prevalent and burdensome condition. Generic utility measures may fail to
reflect its full impact on patients’ health status. The Incontinence Utility Index (IUI) is a community-based preference
index derived from the Incontinence Quality of Life Questionnaire (I-QOL) developed to value health states related
to urinary symptoms in patients with neurogenic detrusor overactivity. This study assessed the measurement
properties of the IUI in patients with idiopathic overactive bladder (OAB).
Methods: Data were used from two clinical trials which recruited patients with OAB whose symptoms were
inadequately managed with ≥1 anticholinergic medication. Psychometric evaluation included: Differential Item
Functioning (DIF) analysis, concordance between I-QOL and IUI (Intraclass correlation coefficient [ICC], criterion and
convergent validity according to relevant patient reported outcomes and clinical variables (Spearman’s correlation
coefficient, rho), responsiveness, and agreement between utility measures (ICC and Bland-Altman method).
Results: A total of 1,105 idiopathic OAB patients were included. Mean age (range) was 60.4 years (18–90), 87.8 %
(n = 970) were female. DIF was identified in 3 items, none of which are contained in the IUI. ICC (CI95 %) was 0.944
(0.936–0.950). Statistically significant differences (p < 0.001) were found in IUI scores for patients improving
according to the Treatment Benefit Scale (TBS). Moderate to strong correlations (rho > |0.6|) were found in the
expected direction with daily incontinence, urgency episodes and disease-specific domains of King’s Health
Questionnaire (KHQ). Low to moderate correlations (rho:<|0.6|) were found with Short Form version 2 (SF-12v2)
summary components. A large effect size was found for patients reporting improvement (0.98–1.21) or great
improvement (1.87–2.56) in the TBS, as well as in patients responding to treatment (1.19–2.40). Across utility
measures, directional trends were consistent with OAB symptom profile, however, a lack of agreement in absolute
values was observed.
Conclusions: The IUI presents good psychometric properties for valuing the impact of UI-related problems in
idiopathic OAB patients.
Trial registration: ClinicalTrials.gov: NCT00910845 and NCT00910520.
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Background
Overactive bladder (OAB) is defined by the International
Continence Society as “urgency, with or without urge in-
continence, usually with frequency and nocturia” [1].
Prevalence rates of OAB range from 12 to 20 % in men
and women and increase with age in both populations
[2–5]. Previous research has shown that OAB, especially
when accompanied with urinary incontinence (UI) or ur-
gency urinary incontinence (UUI), considerably impacts
patients’ health related quality of life (HRQoL) [6–9],
affecting domains related to emotional well-being and
social participation (e.g., avoidance and limiting behav-
iours) [7, 8], and also resulting in decreased work prod-
uctivity [7, 10, 11].
Preference-based values, or utilities, are commonly
used in health economics to weight health states associ-
ated with different conditions. These outcomes are of
importance for economic resources allocation because
they allow for estimation of Quality-Adjusted Life-Years
(QALYs) by multiplying life expectancy with the utility
value associated with a given health state. The QALY is
considered an appropriate measure of health benefit be-
cause it reflects both mortality and health-related quality
of life (HRQoL) impacts associated with a health condition
[12]. Among the available approaches to obtain utilities,
the administration of currently existing generic preference-
based instruments such as the EuroQol-5D [EQ-5D])
[13–15] is commonly preferred by different health tech-
nology agencies in favor of promoting consistency and
equity in decision-making and making this process
more practical [12, 16–18]. However, in cases where
generic utility instruments may not capture clinically
important changes, as has been shown among patients
with UI related problems [19, 20], disease-specific
community-based utility instruments may be consid-
ered more appropriate.
The Incontinence Utility Index (IUI) was recently
created for measuring the health states related to urin-
ary symptoms in neurogenic patients with OAB and UI
symptoms [21]. This tool was derived from the previ-
ously validated I-QOL questionnaire and its neurogenic
module [22, 23] in accordance with the latest methodo-
logical recommendations [24]. The I-QOL is a widely
used instrument in clinical research to address patients’
HRQoL associated with experiencing urinary problems
[8, 22, 25, 26]. Development of the IUI was com-
prised of two stages and has been described in detail
previously [21].
The IUI was originally developed from a sample of pa-
tients with neurogenic detrusor overactivity (NDO) and
UI related symptoms, hence new research is needed to
support use of this instrument in other populations ex-
periencing lower urinary tract symptoms. Consequently,
the present study was conducted to test the measurement
properties of the IUI among patients with idiopathic OAB.
The performance of the abbreviated health state classifica-
tion system underlying the IUI and the utility estimates
resulting from its application were compared with the
original I-QOL and two other utility measures collected
from the same sample, respectively.
Methods
Sample
OAB cases included in the present analysis were adult
patients with idiopathic OAB and UI, participating in
two multicenter, international, Phase 3, randomized,
double-blind, placebo-controlled studies to evaluate the
safety and efficacy of a single treatment of BOTOX®
(onabotulinumtoxinA, Allergan Inc.). Eligible patients
had idiopathic OAB with UI, were considered to be
inadequately managed by anticholinergic therapy (insuf-
ficient efficacy or intolerable side effects), and expe-
rienced ≥3 episodes of urinary urgency incontinence
(UUI) in a 3-day patient bladder diary, an average of ≥ 8
micturitions per day and a post-void residual urine vol-
ume ≤100 ml. A full description of their characteristics
and study design can be found elsewhere [27, 28].
In order to test the differential item functioning by sam-
ple etiology, the sample originally used for item selection
of the IUI is also included in this study. This sample was
comprised of patients with UI due to NDO as a result of
spinal cord injury or multiple sclerosis, recruited during
two multicenter, double-blind, randomized, placebo-
controlled, parallel-group studies [29, 30].
Ethics, consent and permissions
Before entering in the aforementioned clinical trials all
patients had to provide their written informed consent
and all the studies were conducted in full compliance
with the ethical principles regarding human experimen-
tation of the Declaration of Helsinki. The New York
University School of Medicine IRB, with Federal Wide
Assurance number 00004952 reviewed the studies.
Clinical variables and outcomes measures
Basic clinical and socio-demographic data were collected
to describe the sample of the study. The following patient
reported outcomes (PROs) were administered to patients
in these studies:
– Treatment Benefit Scale (TBS) [31]: a single-item
measure that evaluates patients’ perception of
benefit following treatment. Responses are defined
as 1 = greatly improved; 2 = improved; 3 = not
changed; 4 = worsened. The TBS has demon-
strated validity and responsiveness in previous
clinical trials with antimuscarinic treatments in
patients with OAB [31].
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– Short Form-12 Health Survey version 2 (SF-12)
[14, 32, 33]: A generic HRQoL questionnaire that
includes 12 items from the SF-36 Health Survey
[34] and has two component summary scores
(physical –PCS- and mental –MCS-). Scores from
patients’ responses are normalized to a distribution of
50 ± 10 (using U.S. general population norms), and a
higher score indicates better HRQoL. It has demon-
strated adequate psychometric properties to estimate
the health burden of chronic conditions in general
population surveys [33, 35]. A preference-based
weighted index can be estimated from this instrument
(SF-6D) following the models proposed by Brazier et
al. [14]. The range of the observed utility values
varies between 0.30 (worst health state) to 1.0
(best health state) [36].
– King’s Health Questionnaire (KHQ) [37, 38]: This self-
administered disease-specific HRQoL questionnaire
for UI has 21 items (4-point Likert scale) covering 8
domains: urinary symptom severity, role limitations,
physical functioning, social functioning, emotional
problems, personal relationships, sleep disturbance,
and general health. The range of scores for each
domain is between 0 and 100, with higher scores
indicating greater impact on patients’ HRQoL
(worse perceived health status). A condition-specific
preference-based index has been developed from this
instrument through reducing the number of dimen-
sions (from 8 to 5), and valuing the resulting health
state classification framework using direct elicitation
(standard gamble) in a representative sample of
patients with UI attending UK hospital outpatients
clinics. Different models were tested to better adjust
the predicting valuations for all the possible health
states defined by this utility measure (n = 1024) [38].
Mean utility values obtained with the KHQ range
from 0.77 to 0.98.
– Incontinence Quality of Life Questionnaire (I-QOL)
[22, 23, 26]: This self-administered questionnaire
comprises 22 items (5 Likert point) distributed into
three dimensions. These principal domains are:
avoidance and limiting behavior (items 1–4, 10, 11,
13 and 20), psychosocial impact (items 5–7, 9,
15–17, 21 and 22), and social embarrassment
(items 8, 12, 14, 18 and 19). A total scale score is
calculated by summing the scores of all items included
in an scale and transforming them into a 0–100 scale
(higher scores reflect better HRQoL) [22].
The abbreviated health states classification system
comprises 5 items or attributes (Fig. 1). Utility scores
can be derived from this instrument by applying the
IUI algorithm: IUI utility score = 1.051 (b1 * b2 * b3 *
b4 * b5)—0.051, where b is the estimated weight
attached to the 3 different levels of each of the 5 attri-
butes. The IUI has a utility score ranging from 0.036
(worst health state) to 1 (perfect health) [21].
Statistical approach
A number of analyses were undertaken to assess the
performance of the IUI in this sample of OAB patients:
Rasch analysis was used to check for the presence of
differential item functioning (DIF, or measurement bias)
of the I-QOL between patients with OAB and NDO pa-
tients from which the IUI was originally developed.
Items were calibrated and subjects were scored using
the Partial Credit Model [39]. DIF was tested by seg-
menting the sample by etiology [40]. The presence of
DIF suggests that patients with the same disease severity
tend to respond differently to an item depending on
their disease etiology. DIF was considered significant
with p < 0.001, and relevant if the difference between
groups exceeded 0.5 logits.
In addition, further tests were applied to assess the
psychometric performance of the abbreviated health
state classification defined in the IUI and the associated
utility scores in this sample of OAB patients.
Concordance between I-QOL versions
The agreement between the original I-QOL and its ab-
breviated health state classification system in OAB pa-
tients was analyzed by applying the intraclass correlation
coefficient (ICC) at baseline and at week 12. Two-way
mixed effects models (people effects are random and
measures effects are fixed) was applied with an absolute
agreement type with average measures (reliability of the
mean of the instruments). It is generally recommended
that ICC be at least 0.7 [41], with higher values indicat-
ing better concordance.
Validity
Criterion validity was assessed by studying the differ-
ences in both the I-QOL and the abbreviated form ac-
cording to TBS scores at Week 12. Kruskal-Wallis (with
Bonferroni’s correction for multiple comparisons) tests
were conducted for this purpose. Statistically significant
differences between TBS levels (p < 0.05) were expected
in the scores of the I-QOL and its derived measures.
Next, the relationship between the I-QOL, its abbreviated
health state classification system, and the IUI with other
PRO and clinical variables were evaluated. Spearman rank
correlations coefficients (rho) were calculated between
these instruments and the following clinical variables: age,
volume voided per micturition (mL/24 h), daily incontin-
ence episodes, daily urgency episodes, daily micturition
episodes, daily incontinence urgency episodes, number of
daily nocturia episodes and weekly incontinence episodes.
Finally, convergent validity of the I-QOL, the abbreviated
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health state classification system, and the IUI were studied
by testing its association (rho) with respect to the KHQ
global score and domains, the SF-12 (Physical and Mental
Component Summaries) and the utility scores derived
from the KHQ and the SF-12 using Spearman rank correl-
ation. A moderate to strong association (rho ≥0.5) was
expected between the I-QOL and other disease-specific
variables (e.g., disease-specific domains of the KHQ or
the number of incontinence episodes), while the associ-
ation between the I-QOL and variables less directly re-
lated to OAB (e.g., generic domains of the KHQ and
the SF-12 summary components) was hypothesized to
be lower (rho between 0.3 and 0.49).
Responsiveness
The ability of the abbreviated form of the I-QOL and
the IUI to capture clinically relevant changes in OAB pa-
tients were analyzed according to the level of response
to treatment and TBS scale. To this end, differences in
scores between baseline and Week 12 visits were calcu-
lated via Wilcoxon tests, standardized response means
(SRMs) and effect size statistics. Patients were classified
as respondents according to clinical criteria depending
on the average percentage reduction in daily UI episodes
from baseline: 50 %, 75 % or 100 % of reduction in daily
episodes according to the 3-day bladder diary at week 12
[42]. SRMs were calculated as the mean change score
(score at week12 minus score at baseline) divided by the
standard deviation of change score. Effect size statistics
were calculated as the mean change score divided by the
standard deviation at baseline [8]. It was hypothesized
that higher effect sizes were to be found between pa-
tients with a higher response or perceived benefit at
week 12. Conventional benchmarks to interpret effect
sizes are as follows: an effect size of 0.2–0.49 is consid-
ered small, 0.5–0.79 medium and over 0.8, large [43].
Fig. 1 Incontinence Utility Index (IUI) attributes and levels
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Agreement between utility measures
Bland-Altman diagrams for agreement and the ICC stat-
istic (with a two-way mixed effects model and checking
an absolute agreement type with average measures) at
baseline and Week 12 were used to study to what extent
the utility values from the IUI and those obtained from
the SF-12 [14] and the KHQ [38] could be interchange-
able. The limits of agreement in the Bland-Altman figures
were defined at a distance from the mean of 1.96 times
the standard deviation of the differences. Acceptable limits
of concordance of ± 0.1 points from 0 (maximum
concordance in mean values) are also displayed to
represent relevant discrepancies in common utility
scales [44, 45].
The statistical packages SPSS 21.0 and Winsteps 3.75
were used to conduct the analyses above.
Results
A total of 1,105 idiopathic OAB patients with UI symp-
toms were included. A majority of them were female
(87.8 %) and Caucasian (90.9 %). Mean age (range) was
60.4 years (18 to 90). Patients had a median duration of
OAB of 5 years and reported a mean (SD) of 5.44 (3.62)
daily UI episodes, 4.90 (3.43) daily urgency urinary in-
continence episodes, 11.74 (3.78) daily micturitions, 8.57
(4.40) daily urgency episodes, and 2.11 (1.42) nocturia
episodes per day at study baseline. A summary of select
patient demographic and clinical characteristics can be
found in Table 1.
Rasch analysis showed three items presented statisti-
cally significant differential item functioning with a rele-
vant effect with respect to etiology of urinary symptoms
(neurogenic vs. idiopathic). Details can be found on
Table 2. Items exhibiting DIF included content related
to trips to the toilet, aging and sexual activity. However,
as none of the affected items were included in develop-
ment of attributes and subsequent preference elicitation
for the IUI no further action was deemed necessary.
A high level of agreement was found between the abbre-
viated form of the I-QOL and the original version at both
baseline and week 12: ICC = 0.900 (CI 95 %: 0.886–0.912)
and 0.944 (CI 95 %: 0.936–0.950). A statistically significant
difference was seen for I-QOL scores, the abbreviated
health state descriptive system, and the IUI scores across
perceived benefit levels after 12 weeks of treatment
(TBS scale, Kruskal-Wallis Test p < 0.001, Table 3).
Pairwise comparisons with Bonferroni correction were
also statistically significant, with exception of scores be-
tween patients who indicated that their health condi-
tion had either not changed or worsened.
Table 4 shows the relationship between I-QOL versions,
clinical variables and other HRQoL instruments. As hy-
pothesized, correlation coefficients reflected a negative
and moderate to strong association between I-QOL
versions and those clinical variables related to UI prob-
lems (rho > |0.6|): daily incontinence episodes and urgency
episodes, indicating that greater frequency of UI related
problems was associated with lower I-QOL scores. Age
was not significantly related to I-QOL scores. Further-
more, the scores obtained from the I-QOL and its derived
instruments were negative and moderately to strongly as-
sociated with disease-specific HRQoL domains of the
KHQ (rho > |0.6–0.8|), with the Severity Measures and
Emotions domains having the strongest relationship to
I-QOL measures. As expected, the association with the
summary components of the SF-12, a measure of gen-
eral HRQoL, were positive but low to moderate: low
Table 1 Select baseline demographic, clinical, and patient-
reported characteristics: OAB pooled study population
Variables Baseline
n Mean SD
Age 1105 60.36 13.90
Female (n, %) 970 87.8 %
Caucasian (n, %) 1004 90.90 %
Duration of OAB (years) 1104 6.09 7.07
Volume Voided Per Micturition (mL/24 h) 1021 153.60 62.57
Daily Micturition Episodes 1026 11.74 3.78
Daily Incontinence Episodes 1026 5.44 3.62
Daily Urgency Episodes 1026 8.57 4.40
Daily Urinary Urgency Incontinence Episodes 1026 4.90 3.43
Daily Nocturia Episodes 1026 2.11 1.42
I-QOL Total Summary Score 1101 34.42 18.77
I-QOL Avoidance and Limiting Behavior Score 1103 31,43 16.99
I-QOL Psychosocial Impacts Score 1103 42.62 24.29
I-QOL Social Embarrassment Score 1103 24.69 20.93
I-QOL Abbreviated Form 1100 36.12 18.31
IUI Scores 1100 0.22 0.14
KHQ Domains
General Health Perceptions Score 1099 31.76 23.82
Incontinence Impact Score 1099 83.35 23.91
Role Limitations Score 1099 63.32 29.04
Social Limitations Score 1099 43.59 30.97
Personal Relationships Score 834 37.03 35.70
Emotions Score 1099 55.67 30.30
Sleep/Energy Score 1099 65.00 26.77
Severity Measures Score 1099 65.12 22.97
King’s Health Questionnaire (KHQ) Utility Score 1099 0.93 0.02
SF-12v2 Outcomes
Physical Component Summary Score (PCS) 1096 43.22 10.03
Mental Component Summary Score (MCS) 1096 43.19 11.98
SF-12v2 Health Survey Utility Score (SF-6D) 1096 0.66 0.13
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Table 2 Rasch analysis: differential item functioning by etiology (NDO vs. OAB)
Item NDO measure NDO S.E. OAB measure OAB S.E. DIF contrast Welch t p-value
1 I worry about getting to toilet in time 0.30 0.04 0.65 0.04 −0.35 −6.03 <0.001
2 I worry about coughing and sneezing −1.17 0.04 −0.85 0.03 −0.31 −6.50 <0.001
3 I’m careful when standing up −0.95 0.04 −0.71 0.03 −0.24 −5.07 <0.001
4 I worry about where toilets are located 0.36 0.04 0.61 0.04 −0.24 −4.33 <0.001
5 I feel depressed due to urinary problema −0.35 0.04 −0.26 0.03 −0.08 −1.65 0.099
6 I don’t feel free to leave my home −0.21 0.04 −0.35 0.03 0.14 2.94 0.003
7 I’m prevented from doing what I want 0.24 0.04 0.10 0.03 0.14 2.62 0.009
8 I worry about a urine smell on mea −0.40 0.04 −0.33 0.03 −0.06 −1.33 0.184
9 Urine problems are always on my mind 0.50 0.05 0.50 0.04 0.00 0.00 1.000
10 I make frequent trips to the toilet 0.27 0.04 0.96 0.04 −0.69 −11.3 <0.001
11 Important to plan details in advance 0.30 0.05 −0.09 0.03 0.39 6.93 <0.001
12 I worry urine problems will worsen w/age 0.27 0.04 0.86 0.04 −0.59 −10.3 <0.001
13 I can’t get a good night of sleepa −0.13 0.04 0.03 0.03 −0.17 −3.39 0.001
14 I worry about being embarrassed 0.41 0.04 0.39 0.03 0.02 0.42 0.674
15 I feel like I’m not a healthy person −0.34 0.04 −0.56 0.03 0.22 4.45 <0.001
16 I feel helpless due to urinary problems −0.52 0.04 −0.52 0.03 0.00 0.00 1.000
17 I get less enjoyment out of life −0.16 0.04 −0.26 0.03 0.10 2.00 0.045
18 I worry about wetting myself 0.83 0.05 0.81 0.04 0.02 0.34 0.735
19 I feel I can’t control my bladdera 1.12 0.05 0.74 0.04 0.37 5.68 <0.001
20 I watch what and how much I drinka 0.51 0.05 0.36 0.03 0.15 2.61 0.009
21 My choice of clothing is limited −0.53 0.04 −0.68 0.03 0.15 3.13 0.002
22 I worry about having sex −0.55 0.03 −1.14 0.03 0.59 13.13 <0.001
DIF: differential item functioning aItems which constitute the descriptive system of the IUI. DIF contrast in bold indicate items which exhibited differential
item functioning
Table 3 Differences in the I-QOL and IUI scores according to the Treatment Benefit Scale (TBS) at week 12
Treatment benefit scale Number Mean SD 95 % CI for mean p-value
Lower Upper
I-QOL scale score Greatly improve 187 77.49 20.70 74.51 80.48 <0.001
Improved 274 57.36 22.69 54.67 60.06
Not changeda 464 37.21 20.42 35.35 39.08
Worseneda 109 31.46 19.95 27.67 35.25
Scale score of the abbreviated
form of the I-QOL
Greatly improve 187 72.19 20.77 69.20 75.19 <0.001
Improved 274 54.71 19.97 52.33 57.08
Not changeda 464 37.95 19.23 36.20 39.71
Worseneda 109 33.58 18.64 30.04 37.12
IUI scores Greatly improve 187 0.60 0.27 0.56 0.64 <0.001
Improved 274 0.39 0.20 0.37 0.42
Not changeda 464 0.24 0.16 0.23 0.25
Worseneda 109 0.21 0.14 0.18 0.23
aAfter applying Bonferroni’s correction, all comparisons established by TBS levels were significant with the exception of that between not changed vs
worsened levels
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Table 4 Responsiveness of I-QOL and IUI across clinical criteria at week 12
Change scorea p-value SRMsb Effect size
Number Mean SD Lower limit Upper limit
TBSc Greatly improve
- Abbreviated I-QOL 186 34.62 22.78 31.33 37.92 <0.001 1.52 1.87
- Original I-QOL 187 42.79 21.72 39.66 45.92 <0.001 1.97 2.24
- IUI 186 0.37 0.27 0.33 0.41 <0.001 1.37 2.56
TBS Improved
- Abbreviated I-QOL 274 18.14 19.64 15.76 20.40 <0.001 0.92 0.98
- Original I-QOL 274 22.80 19.82 20.40 25.08 <0.001 1.15 1.21
- IUI 274 0.16 0.19 0.14 0.19 <0.001 0.87 1.14
TBS Not changed
- Abbreviated I-QOL 462 1.90 15.86 0.56 3.47 0.017 0.12 0.11
- Original I-QOL 462 2.20 13.84 0.98 3.51 0.004 0.16 0.12
- IUI 462 0.02 0.13 0.00 0.03 0.031 0.12 0.12
TBS Worsened
- Abbreviated I-QOL 109 −0.73 15.97 −3.77 2.30 0.502 −0.05 −0.04
- Original I-QOL 109 −1.09 14.01 −3.75 1.57 0.376 −0.08 −0.06
- IUI 109 −0.01 0.13 −0.03 0.02 0.363 −0.05 −0.05
Responderd 50 % = 0 (No)
- Abbreviated I-QOL 552 2.79 16.86 1.49 4.36 <0.001 0.17 0.16
- Original I-QOL 552 2.82 14.89 1.65 4.19 <0.001 0.19 0.16
- IUI 552 0.02 0.14 0.01 0.03 <0.001 0.16 0.17
Responder 50 % = 1 (Yes)
- Abbreviated I-QOL 470 22.47 23.09 20.34 24.49 <0.001 0.97 1.19
- Original I-QOL 471 28.51 24.01 26.29 30.60 <0.001 1.19 1.50
- IUI 470 0.23 0.25 0.20 0.25 <0.001 0.90 1.52
Responder 75 % = 0 (No)
- Abbreviated I-QOL 697 5.05 17.89 3.77 6.46 <0.001 0.28 0.28
- Original I-QOL 697 5.85 17.29 4.61 7.20 <0.001 0.34 0.32
- IUI 697 0.04 0.15 0.03 0.05 <0.001 0.28 0.32
Responder 75 % = 1 (Yes)
- Abbreviated I-QOL 325 26.40 23.65 23.85 28.94 <0.001 1.12 1.41
- Original I-QOL 326 33.46 23.76 30.86 35.96 <0.001 1.41 1.75
- IUI 325 0.28 0.27 0.25 0.31 <0.001 1.05 1.80
Responder 100 % = 0 (No)
- Abbreviated I-QOL 843 7.38 19.10 6.12 8.72 <0.001 0.39 0.41
- Original I-QOL 843 9. 18 19.58 7.88 10.54 <0.001 0.47 0.50
- IUI 843 0.06 0.17 0.05 0.08 <0.001 0.38 0.48
Responder 100 % = 1 (Yes)
- Abbreviated I-QOL 179 32.85 23.97 29.21 36.12 <0.001 1.37 1.79
- Original I-QOL 180 40.26 22.99 36.69 43.30 <0.001 1.75 2.10
- IUI 179 0.36 0.28 0.32 0.40 <0.001 1.29 2.40
aChange score = scores at week 12 minus scores at baseline
bSRM: Standardized response means
cTBS: Treatment Benefit Scale
dResponder: calculated from the average percentage of reduction in daily UI episodes from baseline
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\with respect to the physical component summary score
(rho range: 0.25–0.31) and moderate relative to the mental
component summary score (rho range = 0.47–0.52).
The responsiveness of I-QOL versions was evaluated
using SRMs and effect sizes by week 12 TBS levels and
responder definitions (Table 4). Scores from patients
who reported an improvement in symptoms corre-
sponded with a large effect size in all the I-QOL derived
instruments (range: 0.98–1.21), with scores from pa-
tients reporting symptoms had “Greatly improved”
showing higher effect sizes (range: 1.87–2.56). Further-
more, effect sizes were low between those patients
reporting no changes or being worse at week 12 from
baseline (range: 0.04–0.12). The same trend was ob-
served in the case of the responder classification imple-
mented according to the percentage of UI episodes
reduction: the higher the reduction in the frequency of
UI related symptoms, the higher the effect sizes. For
instance, between patients reporting a benefit of 50 %
of reduction in UI episodes, effect sizes ranged from
1.19 to 1.52 while among those with 100 % reduction
the range was 1.79–2.40.
With regards to the concordance between utility values,
although the associations between the IUI and the utilities
scores from the KHQ and the SF-12 (SF-6D) were signifi-
cant, positive and moderate to strong (0.761 and 0.469, re-
spectively, p < 0.001) (Table 5), Bland-Altman methods
highlighted poor agreement between these measures
meaning that large differences in utility values were seen
in the scatterplots (Figs. 2, 3 and 4). Mean differences
(SD) between utility values from IUI and both KHQ and
SF-6D were: −0.70 (0.13) and −0.44 (0.15) at baseline and
−0.60 (0.22) and −0.34 (0.22) at week 12, respectively. The
agreement between the utility scores obtained from the
KHQ and the SF-6D was also low: mean differences of
values (SD) was 0.27 (0.12) at baseline and 0.26 (0.12) at
week 12, far exceeding acceptable concordance thresholds.
This low agreement was confirmed by ICC results: all the
comparisons (at baseline and at week 12) were under the
accepted threshold (0.7) and ranged from 0.014 to 0.2.
Discussion
This study presents the measurement properties of the
IUI in a sample of idiopathic OAB patients with UI
Table 5 Association between I-QOL and IUI scores with clinical variables and measures at week 12
I-QOL Scale score Abbreviated form of the I-QOL Scale score IUI Scores
Age in Years (n = 1038) −0.038* −0.026* −0.032*
Volume Voided Per Micturition (n = 1021) 0.227** 0.236** 0.233**
Daily Incontinence Episodes (n = 1026) −0.627** −0.579** −0.594**
Daily Micturition Episodes (n = 1026) −0.375** −0.359** −0.347**
Daily Urgency Episodes (n = 1026) −0.537** −0.515** −0.510**
Daily Incontinence Urgency Episodes (n = 1026) −0.638** −0.589** −0.603**
Daily Nocturia Episodes (n = 1026) −0.315** −0.333** −0.300**
Weekly Incontinence Episodes (n = 1025) −0.626** −0.579** −0.594**
I-QOL: Avoidance and Limiting Behavior Score (n = 1038) 0.941** 0.853** 0.842**
I-QOL: Psychosocial Impacts Score (n = 1038) 0.964** 0.846** 0.841**
I-QOL: Social Embarrassment Score (n = 1038) 0.930** 0.873** 0.891**
KHQ Utility Score (n = 1038) 0.827** 0.775** 0.761**
General Health Perceptions Score (n = 1036) −0.228** −0.195** −0.193**
Physical functioning (n = 1036) −0.775** −0.701** −0.698**
Role Limitations Score (n = 1038) −0.783** −0.696** −0.693**
Social Limitations Score (n = 1038) −0.755** −0.668** −0.660**
Personal Relationships Score (n = 761) −0.587** −0.517** −0.510**
Emotions Score (n = 1038) −0.807** −0.737** −0.728**
Sleep/Energy Score (n = 1038) −0.617** −0.628** −0.605**
Urinary symptoms severity score (n = 1038) −0.805** −0.763** −0.773**
SF12 Utility Score (SF-6D) (n = 1034) 0.528** 0.476** 0.469**
Physical Component Summary Score (n = 1033) 0.309** 0.252** 0.254**
Mental Component Summary Score (n = 1033) 0.517** 0.477** 0.468**
Spearman correlation coefficient
*p > 0.05 |**p < 0.001
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symptoms who had not been adequately managed with
anticholinergic therapy. The health states covered with
this societal preference-based utility measure were ori-
ginally extracted from the I-QOL and its neurogenic
module using a large sample of adult patients with NDO
[21]. The abbreviated health state classification version
of the I-QOL containing the descriptive system of the
IUI did not include any items from the neurogenic mod-
ule, hence it was appropriate to test its psychometric
performance in idiopathic OAB patients with UI to pro-
vide evidence for use in health economic analyses com-
paring interventions of interest within this patient
population. In a recent study, the I-QOL was shown to
be a robust HRQoL instrument for measuring the im-
pact of urinary problems in similar sample of idiopathic
OAB patients [8] so it was reasonable to further explore
the validity of the IUI in this target population.
Results of the Rasch analysis showed that none of the
items included in the abbreviated health state classifica-
tion system derived from the I-QOL exhibited DIF; that
is, the IUI assigned comparable scores to analogous
health states in NDO and idiopathic OAB patients.
Interestingly, the three I-QOL items which did exhibit
DIF pertained to aspects of life which would be
expected to differ between these two patient popula-
tions (i.e., trips to the toilet, aging, and sexual activity).
NDO patients may have limitations in “Trips to the toi-
let” and “Sexual activity” independently of UI, and their
perspective on aging may be different compared to
those with OAB. Responses on the items whose attributes
were ultimately included in the IUI did not systematically
differ across each sample.
A high level of absolute agreement between the ori-
ginal I-QOL and the descriptive system of the IUI
was demonstrated by the ICC, which showed a very
high proportion of variability that was attributed to
variation between patients. This high degree of con-
cordance indicates that IUI scores are a reliable indi-
cator of urinary symptom impacts as measured by the
I-QOL. In addition, both the abbreviated version of
the I-QOL and the IUI captured significant differ-
ences relative to clinically meaningful variables such
as the reduction in the number of UI episodes or the
treatment benefit perceived by patients as evaluated
by the TBS [31]. Clinically meaningful outcomes rele-
vant to urinary symptoms (daily number of UI epi-
sodes, UUI frequency and nocturia) were moderately
or strongly associated with IUI scores. The large
- - - - Limit of concordance set at 0 ±0.1 in mean differences
.-.-.-. Limits of agreement: mean of differences ± 1.96 * standard deviation of differences.
------ Mean of differences
Fig. 2 Bland-Altman scatterplots: Concordance between Incontinence Utility Index (IUI) and King’s Health Questionnaire (KHQ) utility scores
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effect sizes (d > 0.8) found between baseline and week
12 IUI scores among patients with a reduction in the
frequency of UI symptoms are in accordance to
previous publications using the I-QOL in OAB pa-
tients [8, 22, 46].
Although all utility measures demonstrated consistent
trends (e.g., lower utility values were associated with
poorer urinary symptom profile across all utility mea-
sures), a low level of agreement in absolute values was
systematically found between the utility values estimated
from each of the instruments. IUI utilities had the lowest
absolute values relative to both the KHQ (condition-
specific) and the SF-6D (generic measure) at baseline
and at week 12, while KHQ utility scores were the high-
est. Utility values were more reasonably similar only
among patients whose health state was close to full or
the most desirable health state. This lack of concord-
ance and consistency across different utility measures
to assess overall health status has been frequently de-
scribed in the literature. For instance, this issue has
been addressed when valuing the health states obtained
in obese women with UI [47], or in musculoskeletal
and cardiovascular diseases [48, 49] and in representa-
tive samples of the general population using generic
instruments [50]. In the present study, these discrepan-
cies between the IUI and the KHQ may be due to the
different populations interviewed to derive the health
state classification systems and to estimate the respect-
ive utility indexes. The health states described by the
IUI were valued by the general population while those
of the KHQ were assessed by UI patients attending
hospital outpatient clinics [38]. In other pathologies, it
has been highlighted that patients provided significantly
different values to the health states related to the
disease they experienced in comparison to general
population [51, 52]. Given the existing heterogeneity,
inclusion of more than one utility instrument should be
considered in order to provide a more comprehensive
evaluation of the possible range of the values attached
to the health status of patients with certain health con-
ditions [53].
A number of limitations in the present study should
be addressed. First, although data for the analyses came
from multiple global randomized phase III clinical trials,
further research should be conducted to address region-
specific nuances with respect to self-reported health sta-
tus. The samples utilized in this study are comprised of
a specific subset of patients with urologic problems,
- - - - Limit of concordance set at 0 ±0.1 in mean differences
.-.-.-. Limits of agreement: mean of differences ± 1.96 * standard deviation of differences.
------ Mean of differences
Fig. 3 Bland-Altman scatterplots: Concordance between Incontinence Utility Index (IUI) and Short Form-12 Health Survey (SF-6D) utility scores
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thus, inferences to other urology populations should be
made with caution. Second, the majority of patients in
the OAB studies (87.5 %) were female so additional
testing is required before generalizing these conclusions
to men with OAB. Despite these limitations, the
present research demonstrates the IUI’s ability to detect
clinically important differences in OAB patients with
UI and differentiate well across different levels of re-
ported treatment benefit and symptom improvement.
Thus the psychometric performance of the IUI was
comparable to the original I-QOL.
In conclusion, the IUI is a valid instrument for the as-
sessment of patients with urological symptoms related
to idiopathic OAB. The utilities obtained from its appli-
cation represent the societal value of the health states
described and offers additional insight to researchers
and HTAs when assessing the benefits of urological in-
terventions for OAB and UI problems.
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